Brady W. Dougan - Dec 15, 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: Director, 10%+ Owner
Signature: /s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact
Stock symbol: HUMA
Transactions as of: Dec 15, 2022
Transactions value $: $25,400
Form type: 4
Date filed: 12/19/2022, 07:25 PM
Previous filing: Dec 15, 2022
Next filing: Dec 19, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HUMA	Common Stock	Purchase	$25.4K	+10K	+0.86%	$2.54	1.17M	Dec 15, 2022	By spouse	F1, F2
holding	HUMA	Common Stock						18M	Dec 15, 2022	By Ayabudge LLC
holding	HUMA	Common Stock						510K	Dec 15, 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person's spouse has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase.
F2	The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person's spouse has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase.

The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.